

John M Inadomi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/850259/publications.pdf>

Version: 2024-02-01

272
papers

16,222
citations

18436

62
h-index

16605

123
g-index

312
all docs

312
docs citations

312
times ranked

13153
citing authors

#	ARTICLE	IF	CITATIONS
1	American College of Gastroenterology Guidelines for Colorectal Cancer Screening 2008. American Journal of Gastroenterology, 2009, 104, 739-750.	0.2	1,258
2	American Gastroenterological Association Technical Review on the Management of Barrett's Esophagus. Gastroenterology, 2011, 140, e18-e52.	0.6	968
3	American Gastroenterological Association Medical Position Statement on the Management of Barrett's Esophagus. Gastroenterology, 2011, 140, 1084-1091.	0.6	909
4	Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. Journal of Hepatology, 2000, 32, 142-153.	1.8	838
5	American Gastroenterological Association Institute Guideline on Initial Management of Acute Pancreatitis. Gastroenterology, 2018, 154, 1096-1101.	0.6	591
6	Adherence to Colorectal Cancer Screening. Archives of Internal Medicine, 2012, 172, 575.	4.3	473
7	Nonpolypoid neoplastic lesions of the colorectal mucosa. Gastrointestinal Endoscopy, 2008, 68, S3-S47.	0.5	457
8	Cost-Effectiveness of Colonoscopy in Screening for Colorectal Cancer. Annals of Internal Medicine, 2000, 133, 573.	2.0	428
9	AGA Institute Review of Endoscopic Sedation. Gastroenterology, 2007, 133, 675-701.	0.6	398
10	Consensus Statements for Management of Barrett's Dysplasia and Early-Stage Esophageal Adenocarcinoma, Based on a Delphi Process. Gastroenterology, 2012, 143, 336-346.	0.6	365
11	Screening and Surveillance for Barrett Esophagus in High-Risk Groups: A Cost-Utility Analysis. Annals of Internal Medicine, 2003, 138, 176.	2.0	330
12	The Impact of a Celebrity Promotional Campaign on the Use of Colon Cancer Screening. Archives of Internal Medicine, 2003, 163, 1601.	4.3	329
13	National Institutes of Health Consensus Development Conference Statement: Management of Hepatitis B. Annals of Internal Medicine, 2009, 150, 104.	2.0	329
14	Adverse events in older patients undergoing colonoscopy: a systematic review and meta-analysis. Gastrointestinal Endoscopy, 2011, 74, 885-896.	0.5	219
15	American Gastroenterological Association Institute Technical Review on the Use of Thiopurines, Methotrexate, and Anti-TNF Biologic Drugs for the Induction and Maintenance of Remission in Inflammatory Crohn's Disease. Gastroenterology, 2013, 145, 1464-1478.e5.	0.6	196
16	AGA Clinical Practice Guidelines on the Management of Mild-to-Moderate Ulcerative Colitis. Gastroenterology, 2019, 156, 748-764.	0.6	194
17	Lansoprazole Treatment of Patients With Chronic Idiopathic Laryngitis: A Placebo-Controlled Trial. American Journal of Gastroenterology, 2001, 96, 979-983.	0.2	186
18	Step-down management of gastroesophageal reflux disease. Gastroenterology, 2001, 121, 1095-1100.	0.6	177

#	ARTICLE	IF	CITATIONS
19	A Cost-Utility Analysis of Ablative Therapy for Barrett's Esophagus. <i>Gastroenterology</i> , 2009, 136, 2101-2114.e6.	0.6	174
20	Risks Associated With Anesthesia Services During Colonoscopy. <i>Gastroenterology</i> , 2016, 150, 888-894.	0.6	167
21	Step-down from multiple- to single-dose proton pump inhibitors (PPIs): a prospective study of patients with heartburn or acid regurgitation completely relieved with PPIs. <i>American Journal of Gastroenterology</i> , 2003, 98, 1940-1944.	0.2	162
22	Systematic Review of the Predictors of Recurrent Hemorrhage After Endoscopic Hemostatic Therapy for Bleeding Peptic Ulcers. <i>American Journal of Gastroenterology</i> , 2008, 103, 2625-2632.	0.2	162
23	Prediction of Barrett's Esophagus Among Men. <i>American Journal of Gastroenterology</i> , 2013, 108, 353-362.	0.2	159
24	Gut epithelial barrier and systemic inflammation during chronic HIV infection. <i>Aids</i> , 2015, 29, 43-51.	1.0	156
25	Corpus gastritis is protective against reflux oesophagitis. <i>Gut</i> , 1999, 45, 181-185.	6.1	147
26	Association of Hepatitis C Seropositivity With Increased Risk for Developing End-stage Renal Disease. <i>Archives of Internal Medicine</i> , 2007, 167, 1271.	4.3	147
27	The economic impact of irritable bowel syndrome. <i>Alimentary Pharmacology and Therapeutics</i> , 2003, 18, 671-682.	1.9	146
28	The Cost Effectiveness of Radiofrequency Ablation for Barrett's Esophagus. <i>Gastroenterology</i> , 2012, 143, 567-575.	0.6	143
29	Magnitude and Economic Impact of Inappropriate Use of Stress Ulcer Prophylaxis in Non-ICU Hospitalized Patients. <i>American Journal of Gastroenterology</i> , 2006, 101, 2200-2205.	0.2	142
30	Screening and prevention of colorectal cancer. <i>BMJ</i> , The, 2021, 374, n1855.	3.0	141
31	Overutilization of Proton Pump Inhibitors: A Review of Cost-Effectiveness and Risk in PPI. <i>American Journal of Gastroenterology</i> , 2009, 104, S27-S32.	0.2	139
32	The Effect of Endoscopic Surveillance in Patients With Barrett's Esophagus: A Systematic Review and Meta-analysis. <i>Gastroenterology</i> , 2018, 154, 2068-2086.e5.	0.6	128
33	Projections of demand and capacity for colonoscopy related to increasing rates of colorectal cancer screening in the United States. <i>Alimentary Pharmacology and Therapeutics</i> , 2004, 20, 507-515.	1.9	125
34	Women patients' preference for women physicians is a barrier to colon cancer screening. <i>Gastrointestinal Endoscopy</i> , 2005, 62, 219-223.	0.5	117
35	Sub-optimal proton pump inhibitor dosing is prevalent in patients with poorly controlled gastro-oesophageal reflux disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2006, 23, 1473-1477.	1.9	116
36	BOB CAT: a Large-Scale Review and Delphi Consensus for Management of Barrett's Esophagus With No Dysplasia, Indefinite for, or Low-Grade Dysplasia. <i>American Journal of Gastroenterology</i> , 2015, 110, 662-682.	0.2	116

#	ARTICLE	IF	CITATIONS
37	Pragmatic classification of superficial neoplastic colorectal lesions. <i>Gastrointestinal Endoscopy</i> , 2009, 70, 1182-1199.	0.5	112
38	The Cost-Effectiveness of CT Colonography in Screening for Colorectal Neoplasia. <i>American Journal of Gastroenterology</i> , 2007, 102, 380-390.	0.2	111
39	Association Between <i>Helicobacter pylori</i> and Barrett's Esophagus, Erosive Esophagitis, and Gastroesophageal Reflux Symptoms. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 239-245.	2.4	110
40	Quality indicators for EGD. <i>Gastrointestinal Endoscopy</i> , 2015, 81, 17-30.	0.5	107
41	Projected increased growth rate of anesthesia professionalâ€ delivered sedation for colonoscopy and EGD in the United States: 2009 to 2015. <i>Gastrointestinal Endoscopy</i> , 2010, 72, 580-586.	0.5	106
42	Magnitude and economic effect of overuse of antisecretory therapy in the ambulatory care setting. <i>American Journal of Managed Care</i> , 2010, 16, e228-34.	0.8	100
43	Adverse events after screening and follow-up colonoscopy. <i>Cancer Causes and Control</i> , 2012, 23, 289-296.	0.8	94
44	Japanese herbal medicine in functional gastrointestinal disorders. <i>Neurogastroenterology and Motility</i> , 2009, 21, 688-696.	1.6	93
45	Adherence to Competing Strategies for Colorectal Cancer Screening Over 3 Years. <i>American Journal of Gastroenterology</i> , 2016, 111, 105-114.	0.2	93
46	Optimising colorectal cancer screening acceptance: a review. <i>Gut</i> , 2015, 64, 1158-1177.	6.1	92
47	National Institutes of Health consensus development conference statement: Management of hepatitis B. <i>Hepatology</i> , 2009, 49, S4-S12.	3.6	91
48	Effect of a prior endoscopy on outcomes of esophageal adenocarcinoma among United States veterans. <i>Gastrointestinal Endoscopy</i> , 2008, 68, 849-855.	0.5	88
49	Screening for Colorectal Neoplasia. <i>New England Journal of Medicine</i> , 2017, 376, 149-156.	13.9	86
50	Cost Utility of Screening for Barrettâ€™s Esophagus With Esophageal Capsule Endoscopy Versus Conventional Upper Endoscopy. <i>Clinical Gastroenterology and Hepatology</i> , 2007, 5, 312-318.	2.4	83
51	Quality Indicators for the Management of Barrettâ€™s Esophagus, Dysplasia, and Esophageal Adenocarcinoma: International Consensus Recommendations from the American Gastroenterological Association Symposium. <i>Gastroenterology</i> , 2015, 149, 1599-1606.	0.6	81
52	What is the best management strategy for high grade dysplasia in Barrett's oesophagus? A cost effectiveness analysis. <i>Gut</i> , 2004, 53, 1736-1744.	6.1	80
53	Esophageal Adenocarcinoma Incidence in Individuals With Gastroesophageal Reflux: Synthesis and Estimates From Population Studies. <i>American Journal of Gastroenterology</i> , 2011, 106, 254-260.	0.2	79
54	Associations of Diabetes Mellitus, Insulin, Leptin, and Ghrelin With Gastroesophageal Reflux and Barrett's Esophagus. <i>Gastroenterology</i> , 2013, 145, 1237-1244.e5.	0.6	78

#	ARTICLE	IF	CITATIONS
55	The AGA Institute Process for Developing Clinical Practice Guidelines Part One: Grading the Evidence. <i>Clinical Gastroenterology and Hepatology</i> , 2013, 11, 329-332.	2.4	73
56	Cost-analysis of prophylactic antibiotics in spontaneous bacterial peritonitis. <i>Gastroenterology</i> , 1997, 113, 1289-1294.	0.6	71
57	Moderate ascites identifies patients with low model for end-stage liver disease scores awaiting liver transplantation who have a high mortality risk. <i>Liver Transplantation</i> , 2011, 17, 129-136.	1.3	70
58	Racial/Ethnic Disparities in Colorectal Cancer Screening Across Healthcare Systems. <i>American Journal of Preventive Medicine</i> , 2016, 51, e107-e115.	1.6	67
59	On-Demand Therapy for Gastroesophageal Reflux Disease. <i>American Journal of Gastroenterology</i> , 2007, 102, 642-653.	0.2	66
60	Projected future increase in aging hepatitis C virus-infected liver transplant candidates: A potential effect of hepatocellular carcinoma. <i>Liver Transplantation</i> , 2012, 18, 1471-1478.	1.3	66
61	Screening for Colorectal Cancer and Evolving Issues for Physicians and Patients. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 2135.	3.8	65
62	Patient Trust in Physician Influences Colorectal Cancer Screening in Low-Income Patients. <i>American Journal of Preventive Medicine</i> , 2014, 47, 417-423.	1.6	64
63	Screening for Hereditary Hemochromatosis in Siblings and Children of Affected Patients: A Cost-Effectiveness Analysis. <i>Annals of Internal Medicine</i> , 2000, 132, 261.	2.0	63
64	A Pilot Study of the Association of Low Plasma Adiponectin and Barrett's Esophagus. <i>American Journal of Gastroenterology</i> , 2008, 103, 1358-1364.	0.2	63
65	Cost-Effective Treatment of Patients with Symptomatic Cholelithiasis and Possible Common Bile Duct Stones. <i>Journal of the American College of Surgeons</i> , 2011, 212, 1049-1060e7.	0.2	61
66	Classification of functional dyspepsia based on concomitant bowel symptoms. <i>Neurogastroenterology and Motility</i> , 2012, 24, 325.	1.6	61
67	Exploring the Recent Trend in Esophageal Adenocarcinoma Incidence and Mortality Using Comparative Simulation Modeling. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 997-1006.	1.1	61
68	Primary-Care Physicians' Perceptions and Practices on the Management of GERD: Results of a National Survey. <i>American Journal of Gastroenterology</i> , 2005, 100, 1237-1242.	0.2	56
69	The impact of colorectal cancer screening on life expectancy. <i>Gastrointestinal Endoscopy</i> , 2000, 51, 517-523.	0.5	54
70	Management of Obscure Occult Gastrointestinal Bleeding: A Cost-Minimization Analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2008, 6, 661-670.	2.4	54
71	Maintenance of Heartburn Relief After Step-Down From Twice-Daily Proton Pump Inhibitor to Once-Daily Dexlansoprazole Modified Release. <i>Clinical Gastroenterology and Hepatology</i> , 2012, 10, 247-253.	2.4	51
72	Cost Effectiveness of Screening Patients With Gastroesophageal Reflux Disease for Barrett's Esophagus With a Minimally Invasive Cell Sampling Device. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 1397-1404.e7.	2.4	51

#	ARTICLE	IF	CITATIONS
73	Development of quality indicators for endoscopic eradication therapies in Barrett's esophagus: the TREAT-BE (Treatment with Resection and Endoscopic Ablation Techniques for Barrett's Esophagus) Consortium. <i>Gastrointestinal Endoscopy</i> , 2017, 86, 1-17.e3.	0.5	50
74	Oesophageal hypersensitivity is associated with features of psychiatric disorders and the irritable bowel syndrome. <i>Alimentary Pharmacology and Therapeutics</i> , 2007, 26, 443-452.	1.9	48
75	Comparing the effectiveness of competing tests for reducing colorectal cancer mortality: a network meta-analysis. <i>Gastrointestinal Endoscopy</i> , 2015, 81, 700-709.e3.	0.5	48
76	Association of Visceral Fat Area, Smoking, and Alcohol Consumption with Reflux Esophagitis and Barrett's Esophagus in Japan. <i>PLoS ONE</i> , 2015, 10, e0133865.	1.1	47
77	Comparing Trends in Esophageal Adenocarcinoma Incidence and Lifestyle Factors Between the United States, Spain, and The Netherlands. <i>American Journal of Gastroenterology</i> , 2014, 109, 336-343.	0.2	45
78	The Impact of a Prior Diagnosis of Barrett's Esophagus on Esophageal Adenocarcinoma Survival. <i>American Journal of Gastroenterology</i> , 2017, 112, 1256-1264.	0.2	45
79	Prevention of Complicated Ulcer Disease Among Chronic Users of Nonsteroidal Anti-inflammatory Drugs. <i>Archives of Internal Medicine</i> , 2002, 162, 2105.	4.3	44
80	Quality Indicators for EGD. <i>American Journal of Gastroenterology</i> , 2015, 110, 60-71.	0.2	44
81	AGA Institute Rapid Review and Recommendations on the Role of Pre-Procedure SARS-CoV-2 Testing and Endoscopy. <i>Gastroenterology</i> , 2020, 159, 1935-1948.e5.	0.6	44
82	Race and Inflammatory Bowel Disease in an Urban Healthcare System. <i>Digestive Diseases and Sciences</i> , 2010, 55, 3479-3487.	1.1	43
83	Hospitalizations are increasing among minority patients with Crohn's disease and ulcerative colitis. <i>Inflammatory Bowel Diseases</i> , 2010, 16, 204-207.	0.9	42
84	Comparisons of Screening Colonoscopy Performed by a Nurse Practitioner and Gastroenterologists. <i>Gastroenterology Nursing</i> , 2011, 34, 210-216.	0.2	40
85	Non-physician performance of lower and upper endoscopy: a systematic review and meta-analysis. <i>Endoscopy</i> , 2014, 46, 401-410.	1.0	39
86	Protective association of colonoscopy against proximal and distal colon cancer and patterns in interval cancer. <i>Gastrointestinal Endoscopy</i> , 2015, 82, 529-537.e1.	0.5	38
87	Development of Quality Indicators for Endoscopic Eradication Therapies in Barrett's Esophagus: The TREAT-BE (Treatment With Resection and Endoscopic Ablation Techniques for Barrett's Esophagus) Consortium. <i>American Journal of Gastroenterology</i> , 2017, 112, 1032-1048.	0.2	38
88	Protective role of gluteofemoral obesity in erosive oesophagitis and Barrett's oesophagus. <i>Gut</i> , 2014, 63, 230-235.	6.1	37
89	An Accurate Cancer Incidence in Barrett's Esophagus: A Best Estimate Using Published Data and Modeling. <i>Gastroenterology</i> , 2015, 149, 577-585.e4.	0.6	37
90	Decision analysis and economic modelling. <i>European Journal of Gastroenterology and Hepatology</i> , 2004, 16, 535-542.	0.8	36

#	ARTICLE	IF	CITATIONS
91	Relationship between diabetes mellitus and adenocarcinoma of the oesophagus and gastric cardia. <i>Alimentary Pharmacology and Therapeutics</i> , 2005, 22, 267-271.	1.9	35
92	The Role of Gastroesophageal Reflux and Other Factors during Progression to Esophageal Adenocarcinoma. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 1012-1023.	1.1	35
93	Ultrasonographic determination of ascitic volume. <i>Hepatology</i> , 1996, 24, 549-551.	3.6	34
94	Quality indicators for gastrointestinal endoscopy units. <i>VideoGIE</i> , 2017, 2, 119-140.	0.3	34
95	Model-Based Estimation of Colorectal Cancer Screening and Outcomes During the COVID-19 Pandemic. <i>JAMA Network Open</i> , 2021, 4, e216454.	2.8	32
96	PPI use in the OTC era: Who to treat, with what, and for how long?. <i>Clinical Gastroenterology and Hepatology</i> , 2005, 3, 208-215.	2.4	31
97	New Model for End Stage Liver Disease Improves Prognostic Capability After Transjugular Intrahepatic Portosystemic Shunt. <i>Clinical Gastroenterology and Hepatology</i> , 2009, 7, 1236-1240.	2.4	31
98	Computational modelling suggests that Barrett's oesophagus may be the precursor of all oesophageal adenocarcinomas. <i>Gut</i> , 2021, 70, 1435-1440.	6.1	31
99	A Combined Paging Alert and Web-Based Instrument Alters Clinician Behavior and Shortens Hospital Length of Stay in Acute Pancreatitis. <i>American Journal of Gastroenterology</i> , 2014, 109, 306-315.	0.2	30
100	Association of gastric intestinal metaplasia and East Asian ethnicity with the risk of gastric adenocarcinoma in a U.S. population. <i>Gastrointestinal Endoscopy</i> , 2018, 87, 1023-1028.	0.5	30
101	Unsedated Small-caliber Esophagogastroduodenoscopy (EGD). <i>Journal of Clinical Gastroenterology</i> , 2001, 33, 210-214.	1.1	29
102	AGA Rapid Review and Guideline for SARS-CoV2 Testing and Endoscopy Post-Vaccination: 2021 Update. <i>Gastroenterology</i> , 2021, 161, 1011-1029.e11.	0.6	29
103	Gastric Cancer in Asian American Populations: a Neglected Health Disparity. <i>Asian Pacific Journal of Cancer Prevention</i> , 2015, 15, 10565-10571.	0.5	29
104	The Laparoscopic Evaluation of Ascites. <i>Gastrointestinal Endoscopy Clinics of North America</i> , 2001, 11, 79-91.	0.6	27
105	A Cost-Utility Analysis of Secondary Prophylaxis for Variceal Hemorrhage. <i>American Journal of Gastroenterology</i> , 2004, 99, 1274-1288.	0.2	27
106	Screening and Surveillance for Barrett's Esophagus: Is It Cost-Effective?. <i>Digestive Diseases and Sciences</i> , 2018, 63, 2094-2104.	1.1	26
107	Implications of Epigenetic Drift in Colorectal Neoplasia. <i>Cancer Research</i> , 2019, 79, 495-504.	0.4	26
108	The cost-effectiveness of biomarkers for predicting the development of oesophageal adenocarcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2005, 22, 135-146.	1.9	25

#	ARTICLE	IF	CITATIONS
109	Ascites improves upon plus serum sodium model for end-stage liver disease (MELD) for predicting mortality in patients with advanced liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2009, 30, 741-748.	1.9	25
110	On-Demand and Intermittent Therapy for Gastro-Oesophageal Reflux Disease. <i>Pharmacoeconomics</i> , 2002, 20, 565-576.	1.7	24
111	Cancer screening in the U.S. through the COVID-19 pandemic, recovery, and beyond. <i>Preventive Medicine</i> , 2021, 151, 106595.	1.6	23
112	Surveillance in Barrett's Esophagus: A Failed Premise. <i>Keio Journal of Medicine</i> , 2009, 58, 12-18.	0.5	23
113	Survival Benefit of Repeat Liver Transplantation in the United States: A Serial MELD Analysis by Hepatitis C Status and Donor Risk Index. <i>American Journal of Transplantation</i> , 2014, 14, 2588-2594.	2.6	22
114	Disparities in colorectal cancer screening in New York City: An analysis of the 2014 NYC Community Health Survey. <i>Cancer Medicine</i> , 2019, 8, 2572-2579.	1.3	22
115	What Multilevel Interventions Do We Need to Increase the Colorectal Cancer Screening Rate to 80%?. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 633-645.	2.4	22
116	Radiofrequency Ablation of Barrett's Esophagus Reduces Esophageal Adenocarcinoma Incidence and Mortality in a Comparative Modeling Analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 1471-1474.	2.4	20
117	Economic analysis of step-wise treatment of gastro-oesophageal reflux disease. <i>Alimentary Pharmacology and Therapeutics</i> , 1999, 13, 1003-1013.	1.9	19
118	Effectiveness and Cost-Effectiveness of Endoscopic Screening and Surveillance. <i>Gastrointestinal Endoscopy Clinics of North America</i> , 2017, 27, 397-421.	0.6	19
119	An Approach to the Primary and Secondary Prevention of Gastric Cancer in the United States. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2218-2228.e2.	2.4	19
120	A simple scoring system to assess the need for an endoscopic intervention in suspected upper gastrointestinal bleeding: A prospective cohort study. <i>Digestive and Liver Disease</i> , 2016, 48, 1180-1186.	0.4	18
121	How to Value Technological Innovation: A Proposal for Determining Relative Clinical Value. <i>Gastroenterology</i> , 2013, 144, 5-8.	0.6	17
122	Surgical vs Endoscopic Management of T1 Esophageal Adenocarcinoma: A Modeling Decision Analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 392-400.e7.	2.4	17
123	Validation of a New Physical Activity Questionnaire for a Sedentary Population. <i>Digestive Diseases and Sciences</i> , 2011, 56, 2678-2687.	1.1	16
124	Esophageal varices on computed tomography and subsequent variceal hemorrhage. <i>Abdominal Imaging</i> , 2014, 39, 251-256.	2.0	16
125	Screening for Colorectal Neoplasia. <i>New England Journal of Medicine</i> , 2017, 376, 1598-1600.	13.9	16
126	Pay for Performance: ACG Guide for Physicians. <i>American Journal of Gastroenterology</i> , 2007, 102, 2119-2122.	0.2	15

#	ARTICLE	IF	CITATIONS
127	Optimizing Management of Patients With Barrett's Esophagus and Low-Grade or No Dysplasia Based on Comparative Modeling. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1961-1969.	2.4	15
128	The Optimal Age to Stop Endoscopic Surveillance of Patients With Barrett's Esophagus Based on Sex and Comorbidity: A Comparative Cost-Effectiveness Analysis. <i>Gastroenterology</i> , 2021, 161, 487-494.e4.	0.6	15
129	The Impact of Peptic Ulcer Disease and Infection With <i>Helicobacter pylori</i> On Life Expectancy. <i>American Journal of Gastroenterology</i> , 1998, 93, 1286-1290.	0.2	14
130	Primary care physician perceptions of non-steroidal anti-inflammatory drug and aspirin-associated toxicity: results of a national survey. <i>Alimentary Pharmacology and Therapeutics</i> , 2006, 23, 655-668.	1.9	14
131	Colorectal Cancer Screening Compliance and Contemplation in Gynecology Patients. <i>Journal of Women's Health</i> , 2010, 19, 911-917.	1.5	14
132	Race/Ethnicity and Primary Language: Health Beliefs about Colorectal Cancer Screening in a Diverse, Low-Income Population. <i>Journal of Health Care for the Poor and Underserved</i> , 2015, 26, 824-838.	0.4	14
133	Increased Post-procedural Non-gastrointestinal Adverse Events After Outpatient Colonoscopy in High-risk Patients. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 883-891.e9.	2.4	14
134	Perceptions on Barriers and Facilitators to Colonoscopy Completion After Abnormal Fecal Immunochemical Test Results in a Safety Net System. <i>JAMA Network Open</i> , 2021, 4, e2120159.	2.8	14
135	Defining a Clinically Significant Adverse Impact of Diagnosing Barrett's Esophagus. <i>Journal of Clinical Gastroenterology</i> , 2006, 40, 109-115.	1.1	13
136	Non-English Speakers Attend Gastroenterology Clinic Appointments at Higher Rates Than English Speakers in a Vulnerable Patient Population. <i>Journal of Clinical Gastroenterology</i> , 2009, 43, 652-660.	1.1	13
137	In Search of Quality Colonoscopy. <i>Gastroenterology</i> , 2008, 135, 1845-1847.	0.6	12
138	Transplant tourism to China: the impact on domestic patient's care decisions. <i>Clinical Transplantation</i> , 2009, 23, 831-838.	0.8	12
139	Why You Should Care about Screening Flexible Sigmoidoscopy. <i>New England Journal of Medicine</i> , 2012, 366, 2421-2422.	13.9	12
140	Recent advances in Barrett's esophagus. <i>Annals of the New York Academy of Sciences</i> , 2018, 1434, 227-238.	1.8	12
141	Effectiveness of a mailed fecal immunochemical test outreach: a Medicare Advantage pilot study. <i>Therapeutic Advances in Gastroenterology</i> , 2020, 13, 175628482094538.	1.4	12
142	Post-endoscopy Esophageal Neoplasia in Barrett's Esophagus: Consensus Statements From an International Expert Panel. <i>Gastroenterology</i> , 2022, 162, 366-372.	0.6	12
143	Taishotoyama Symposium Barriers to colorectal cancer screening: Economics, capacity and adherence. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2008, 23, S198-204.	1.4	11
144	Importance of Determining Indication for Colonoscopy: Implications for Practice and Policy. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 1958-1963.e3.	2.4	11

#	ARTICLE	IF	CITATIONS
145	Greater loss of productivity among Japanese workers with gastroesophageal reflux disease (<sc>GERD</sc>) symptoms that persist <i>vs</i> resolve on medical therapy. <i>Neurogastroenterology and Motility</i> , 2014, 26, 764-771.	1.6	11
146	The impact of medical tourism on colorectal screening among Korean Americans: A community-based cross-sectional study. <i>BMC Cancer</i> , 2016, 16, 931.	1.1	11
147	Cost considerations in implementing a screening and surveillance strategy for Barrett's oesophagus. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2015, 29, 51-63.	1.0	10
148	Colorectal Cancer—Recent Advances and Future Challenges. <i>Gastroenterology</i> , 2020, 158, 289-290.	0.6	10
149	Adherence to Competing Colorectal Cancer Screening Strategies. <i>American Journal of Gastroenterology</i> , 2005, 100, S387-S388.	0.2	10
150	Update on the cost-effectiveness of screening for colorectal neoplasia. <i>Current Opinion in Gastroenterology</i> , 2003, 19, 44-50.	1.0	9
151	Time to Burn? Endoscopic Ablation for Barrett's Esophagus. <i>Gastroenterology</i> , 2011, 141, 417-419.	0.6	9
152	Late Presentation of Colorectal Cancer in a Vulnerable Population. <i>American Journal of Gastroenterology</i> , 2013, 108, 466-470.	0.2	9
153	Risk Stratification in Upper Gastrointestinal Bleeding. <i>Journal of Clinical Gastroenterology</i> , 2007, 41, 559-563.	1.1	8
154	Editorial: Endoscopic Sedation: Who, Which, When?. <i>American Journal of Gastroenterology</i> , 2017, 112, 303-305.	0.2	8
155	Chemoprevention of esophageal adenocarcinoma. <i>Gastroenterology Report</i> , 2020, 8, 253-260.	0.6	8
156	Operationalizing a Rideshare Intervention for Colonoscopy Completion: Barriers, Facilitators, and Process Recommendations. , 2022, 1, .		8
157	Prevalence of gastric cancer versus colorectal cancer in Asians with a positive fecal occult blood test. <i>Indian Journal of Gastroenterology</i> , 2011, 30, 209-216.	0.7	7
158	Endoscopic Screening Program for Control of Esophageal Adenocarcinoma in Varied Populations: A Comparative Cost-Effectiveness Analysis. <i>Gastroenterology</i> , 2022, 163, 163-173.	0.6	7
159	Empiric H ² -blockers for the prophylaxis of variceal hemorrhage: Cost effective or clinically applicable?. <i>Hepatology</i> , 2003, 37, 249-252.	3.6	6
160	Diversity of endoscopy center operations and practice variation across California's safety-net hospital system: a statewide survey. <i>BMC Research Notes</i> , 2013, 6, 233.	0.6	6
161	The Impact of Uncertainty in Barrett's Esophagus Progression Rates on Hypothetical Screening and Treatment Decisions. <i>Medical Decision Making</i> , 2015, 35, 726-733.	1.2	6
162	Masculinity Barriers to Ever Completing Colorectal Cancer Screening among American Indian/Alaska Native, Black, and White Men (Ages 45-75). <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 3071.	1.2	6

#	ARTICLE	IF	CITATIONS
163	Reliability Block Diagrams to Model Disease Management. <i>Medical Decision Making</i> , 1999, 19, 180-185.	1.2	5
164	Reliability block diagrams to model the management of colorectal cancer. <i>Digestive Diseases and Sciences</i> , 1999, 44, 314-321.	1.1	5
165	Evidence Based Medicine (EBM) in Practice: Applying Results of Cost-Effectiveness Analyses. <i>American Journal of Gastroenterology</i> , 2006, 101, 1169-1171.	0.2	5
166	A Cost-Identification Analysis of Screening and Surveillance of Hepatitis C Infection in a Prospective Cohort of Dialysis Patients. <i>Digestive Diseases and Sciences</i> , 2008, 53, 1093-1099.	1.1	5
167	Anesthesia for Colonoscopy: Too Much of a Good Thing?. <i>JAMA Internal Medicine</i> , 2013, 173, 556.	2.6	5
168	Objective Differences in Colonoscopy Technique Between Trainee and Expert Endoscopists Using the Colonoscopy Force Monitor. <i>Digestive Diseases and Sciences</i> , 2018, 63, 46-52.	1.1	5
169	Cost-Effectiveness of Screening, Surveillance, and Endoscopic Eradication Therapies for Managing the Burden of Esophageal Adenocarcinoma. <i>Gastrointestinal Endoscopy Clinics of North America</i> , 2021, 31, 77-90.	0.6	5
170	Colonoscopy Indication Algorithm Performance Across Diverse Health Care Systems in the PROSPR Consortium. <i>EGEMS (Washington, DC)</i> , 2019, 7, 37.	2.0	5
171	An evidence-based medicine approach to economic studies: assessing the cost-effectiveness of competing strategies for colorectal cancer screening. <i>Clinical Gastroenterology and Hepatology</i> , 2003, 1, 404-413.	2.4	4
172	A glossary of economic terms. <i>European Journal of Gastroenterology and Hepatology</i> , 2004, 16, 563-565.	0.8	4
173	The Development of Clinical Guidelines by the American Gastroenterological Association. <i>Gastroenterology</i> , 2010, 138, 417-418.	0.6	4
174	Taxonomy for colorectal cancer screening promotion: Lessons from recent randomized controlled trials. <i>Preventive Medicine</i> , 2017, 101, 229-234.	1.6	4
175	Introduction of Clinical Practice Update Committee Articles. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 4.	2.4	4
176	Exploring Utilities and Outcomes With Infliximab Therapy. <i>Clinical Gastroenterology and Hepatology</i> , 2006, 4, 976-978.	2.4	3
177	Response to Meyer, Dominic et al., and Lin and Schembre. <i>American Journal of Gastroenterology</i> , 2009, 104, 2628-2629.	0.2	3
178	Potential for Lead-Time and Length-Time Biases in Outcomes in Esophageal Adenocarcinoma. <i>American Journal of Gastroenterology</i> , 2009, 104, 3106-3107.	0.2	3
179	Interval Cancers After Colonoscopy: The Importance of Training. <i>American Journal of Gastroenterology</i> , 2010, 105, 2597-2598.	0.2	3
180	Reduced Effectiveness of Standard Recruitment for Deceased Organ Donor Registration: The Need for Population-Specific Recruitment Materials. <i>Digestive Diseases and Sciences</i> , 2011, 56, 1535-1541.	1.1	3

#	ARTICLE	IF	CITATIONS
181	Family History of Colorectal or Esophageal Cancer in Barrett's Esophagus and Potentially Explanatory Genetic Variants. <i>Clinical and Translational Gastroenterology</i> , 2020, 11, e00151.	1.3	3
182	3718 SMALL CALIBER ESOPHAGOGASTRODUODENOSCOPY WITHOUT SEDATION: LESS EXPENSIVE AND LESS TIME CONSUMING THAN CONVENTIONAL ENDOSCOPY.. <i>Gastrointestinal Endoscopy</i> , 2000, 51, AB135.	0.5	2
183	Cost-effectiveness of once in a lifetime screening unsedated endoscopy in 50 year-old white males with uncomplicated GERD. <i>Gastroenterology</i> , 2001, 120, A414.	0.6	2
184	Spontaneous passage of a pancreatic duct stone. <i>Gastrointestinal Endoscopy</i> , 2003, 57, 278-280.	0.5	2
185	Dysphagia drives doctors to diagnose a disease: pitfalls in interpreting observational studies. <i>Gastrointestinal Endoscopy</i> , 2005, 61, 809-811.	0.5	2
186	Response to Fujita and Kapoor. <i>American Journal of Gastroenterology</i> , 2009, 104, 244-245.	0.2	2
187	Projected Growth Rate of Anesthesiologist-Delivered Sedation in Colonoscopy and EGD in the United States: 2009- 2011. <i>Gastrointestinal Endoscopy</i> , 2009, 69, AB111.	0.5	2
188	How to Recognize a Good Guideline. <i>Gastroenterology</i> , 2013, 145, 1179-1181.	0.6	2
189	Follow-up of Positive Fecal Test Results. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 1627.	3.8	2
190	Low-Value Colorectal Cancer Screening. <i>JAMA Network Open</i> , 2018, 1, e185445.	2.8	2
191	Prior Endoscopy Does Not Improve Long-Term Survival from Esophageal Adenocarcinoma among United States Veterans. <i>American Journal of Gastroenterology</i> , 2006, 101, S46-S47.	0.2	2
192	The impact of cumulative colorectal cancer screening delays: A simulation study. <i>Journal of Medical Screening</i> , 2021, , 096914132110451.	1.1	2
193	Novel DNA Methylation Biomarker Panel for Detection of Esophageal Adenocarcinoma and High-Grade Dysplasia. <i>Clinical Cancer Research</i> , 2022, 28, 3761-3769.	3.2	2
194	Chronic corpus gastritis is protective against erosive esophagitis. <i>Gastroenterology</i> , 1998, 114, A113.	0.6	1
195	Cost analysis of alternative therapies for primary and secondary prophylaxis of variceal bleeding. <i>Gastroenterology</i> , 1998, 114, A589.	0.6	1
196	Women's Preference for Women Physicians Is a Barrier to Colorectal Cancer Screening. <i>Gastrointestinal Endoscopy</i> , 2004, 59, P109.	0.5	1
197	Implementing a research project: the nitty gritty. <i>Gastrointestinal Endoscopy</i> , 2006, 64, S7-S10.	0.5	1
198	Tumors of the Stomach. , 2013, , 247-255.		1

#	ARTICLE	IF	CITATIONS
199	Reply. Gastroenterology, 2016, 151, 564.	0.6	1
200	Colorectal Cancer Screening. JAMA Oncology, 2016, 2, 1001.	3.4	1
201	Time to Diagnostic Testing After a Positive Colorectal Cancer Screening Test—Reply. JAMA - Journal of the American Medical Association, 2017, 318, 483.	3.8	1
202	Why “More Research Is Needed,” Despite Overall Certainty: Women and Colorectal Cancer Screening. Annals of Internal Medicine, 2018, 168, 824-825.	2.0	1
203	Racial Disparities in Colorectal Cancer Mortality: the Role of Endoscopy Wait-Time and Stage at Diagnosis. Journal of Racial and Ethnic Health Disparities, 2020, 7, 967-974.	1.8	1
204	Surveillance Cessation for Barrett's Esophagus: A Survey of Gastroenterologists. American Journal of Gastroenterology, 2021, 116, 1730-1733.	0.2	1
205	Magnitude and Economic Impact of Inappropriate Use of Proton Pump Inhibitors for Treatment of Upper Gastrointestinal Disorders in the Ambulatory Care Setting. American Journal of Gastroenterology, 2008, 103, S403.	0.2	1
206	Vascular Lesions. , 0, , 471-478.		1
207	Approach to the Patient with Dysphagia or Odynophagia. , 0, , 1-10.		1
208	Trying to Be American: A Personal Reflection of the Pervasiveness of Systemic Racism and Possible Steps to Mitigate its Impact. Gastroenterology, 2022, , .	0.6	1
209	Clinical and economic impact of population-based screening for hepatitis C: A decision analysis. Gastroenterology, 2000, 118, A1001.	0.6	0
210	Determinants of intestinal metaplasia in the antrum, corpus, and cardia of the stomach. Gastroenterology, 2000, 118, A749.	0.6	0
211	Is step-down from PPIs feasible? Prospective evaluation of a practice guideline for gastroesophageal reflux disease. Gastroenterology, 2000, 118, A212.	0.6	0
212	What is the best management strategy for high grade dysplasia (HGD) in Barrett's esophagus? A cost-effectiveness analysis. Gastroenterology, 2003, 124, A33-A34.	0.6	0
213	I Once Caught a Fish This Big: Endoscopists' Estimate of Polyp Size. Gastrointestinal Endoscopy, 2004, 59, P274.	0.5	0
214	When to stop screening for colorectal cancer. Gastroenterology, 2006, 131, 1355-1357.	0.6	0
215	Patients prefer conventional to virtual colonoscopy. Gastroenterology, 2007, 132, 809-811.	0.6	0
216	Proton Pump Inhibitors and Hip Fracture: Cause for Alarm?. Gastroenterology, 2007, 132, 2063-2065.	0.6	0

#	ARTICLE	IF	CITATIONS
217	Will Virtual Colonoscopy Replace Optical Colonoscopy for Colorectal Cancer Screening?. Gastroenterology, 2007, 133, 1384-1385.	0.6	0
218	Colorectal Cancer Screening in Gynecology Patients. Gastrointestinal Endoscopy, 2007, 65, AB263.	0.5	0
219	Screening for esophageal cancer and Barrett's esophagus. Current GERD Reports, 2007, 1, 185-192.	0.1	0
220	Fear of Loss, Not Promise of Gain, Drives Practice Patterns in Barrett's Esophagus. Gastroenterology, 2008, 134, 1258-1260.	0.6	0
221	Economic Analysis in the Diagnosis and Treatment of Gastrointestinal Diseases. , 0, , 14-19.		0
222	Overutilization of Proton Pump Inhibitors. American Journal of Gastroenterology, 2009, 104, S27-S32.	0.2	0
223	Esophageal Varices On Computed Tomography Predicts Variceal Hemorrhage. Gastrointestinal Endoscopy, 2009, 69, AB355-AB356.	0.5	0
224	Is 325 mg of Prevention Worth a Pound of Cure?. Gastroenterology, 2012, 143, 885-887.	0.6	0
225	Approach to the Patient with Chest Pain. , 2013, , 11-17.		0
226	Diverticular Disease of the Colon. , 2013, , 278-284.		0
227	Development of a Practical Model for Targeting Patient Decision Support Interventions to Promote Colorectal Cancer Screening in Vulnerable Populations. Journal of Health Care for the Poor and Underserved, 2016, 27, 465-478.	0.4	0
228	Introduction to Clinical Practice Update Committee Articles. Gastroenterology, 2016, 151, 45.	0.6	0
229	Endoscopic surveillance or ablation for Barrett's esophagus?. Translational Gastroenterology and Hepatology, 2018, 3, 102-102.	1.5	0
230	What's App with GERD?. Gastroenterology, 2020, 158, 1211-1212.	0.6	0
231	Relationship Between Diabetes Mellitus and Adenocarcinoma of the Esophagus and Gastric Cardia. American Journal of Gastroenterology, 2005, 100, S23.	0.2	0
232	Magnitude and Economic Impact of Inappropriate Use of Stress Ulcer Prophylaxis in Non-Intensive Care Unit Hospitalized Patients. American Journal of Gastroenterology, 2005, 100, S274.	0.2	0
233	Patients That Do Not Speak English Miss Fewer Clinic Appointments Than English Speaking Patients. American Journal of Gastroenterology, 2007, 102, S434.	0.2	0
234	Pilot Study of Colonoscopy by Nurse Practitioner for Colorectal Cancer (CRC) Screening in a Safety Net Healthcare System. American Journal of Gastroenterology, 2008, 103, S549.	0.2	0

#	ARTICLE	IF	CITATIONS
235	Updates in colorectal cancer screening. F1000 Medicine Reports, 2009, 1, .	2.9	0
236	Maintenance of Heartburn Symptom Relief in Patients Stepped-Down from Twice-Daily Proton Pump Inhibitor to Once-Daily Dexlansoprazole MR. American Journal of Gastroenterology, 2011, 106, S5-S6.	0.2	0
237	Structural Anomalies, Tumors, and Diseases of the Biliary Tract. , 0, , 358-365.		0
238	Approach to the Patient with Gastrointestinal Bleeding. , 0, , 18-39.		0
239	Infections of the Gastrointestinal Tract. , 0, , 451-470.		0
240	End-stage Liver Disease. , 0, , 432-442.		0
241	Pancreatic Adenocarcinoma. , 0, , 349-357.		0
242	Colonic Neoplasia. , 0, , 306-322.		0
243	Anorectal Diseases. , 0, , 323-334.		0
244	Biliary Tract Stones and Postcholecystectomy Syndrome. , 0, , 366-376.		0
245	Cholestatic Syndromes. , 0, , 412-419.		0
246	Approach to the Patient with Constipation. , 0, , 89-98.		0
247	Acid Peptic Disorders. , 0, , 232-240.		0
248	Esophageal Tumors. , 0, , 212-220.		0
249	Approach to the Patient with Unexplained Weight Loss. , 0, , 40-47.		0
250	Approach to the Patient with Diarrhea. , 0, , 99-111.		0
251	Disorders of Gastric Emptying. , 0, , 221-231.		0
252	Approach to the Patient with an Abdominal Mass. , 0, , 112-120.		0

#	ARTICLE	IF	CITATIONS
253	Approach to the Patient with Ileus or Obstruction. , 0 , 78-88.		0
254	Motor Disorders of the Esophagus. , 0 , 193-203.		0
255	Approach to the Patient with Abnormal Liver Biochemical Tests. , 0 , 135-147.		0
256	Short Bowel Syndrome. , 0 , 263-269.		0
257	Diseases of the Abdominal Cavity. , 0 , 377-390.		0
258	Nonviral Hepatitis. , 0 , 405-411.		0
259	Autoimmune Liver Disease. , 0 , 427-431.		0
260	Approach to the Patient with Gas and Bloating. , 0 , 70-77.		0
261	Approach to the Patient with Ascites. , 0 , 148-162.		0
262	Approach to the Patient with Abdominal Pain. , 0 , 58-69.		0
263	Approach to the Patient with Jaundice. , 0 , 121-134.		0
264	Approach to the Patient with Nausea and Vomiting. , 0 , 48-57.		0
265	Approach to the Patient Requiring Nutritional Support. , 0 , 163-177.		0
266	Tumors and Other Neoplastic Diseases of the Small Intestine. , 0 , 270-277.		0
267	Approach to the Patient Requiring Endoscopic Procedures. , 0 , 178-191.		0
268	Functional Dyspepsia. , 0 , 241-246.		0
269	Sedation Issues in Colonoscopy: Quality and Economic Considerations. , 2015 , 141-151.		0
270	Issues Related to BID Dosing of PPIs. Gastroenterology and Hepatology, 2010, 6, 369-70.	0.2	0

#	ARTICLE	IF	CITATIONS
271	How to Succeed in Digestive Research. <i>Gastroenterology</i> , 2022, 162, 385-389.	0.6	0
272	The COMPASS study: A prospective, randomized, multi-center trial testing the impact of a clinic-based intervention informing patients of colorectal cancer screening options on screening completion. <i>Contemporary Clinical Trials</i> , 2022, 119, 106852.	0.8	0